Core Viewpoint - Gongdong Medical (605369) is expected to report a significant decline in net profit for 2025, with projections ranging from 44 million to 56 million yuan, representing a year-on-year decrease of 67.37% to 74.36% [2] Group 1: Financial Performance - The company anticipates a net profit attributable to the parent company of 44 million to 56 million yuan for 2025 [2] - This forecast indicates a substantial decline in profitability compared to the previous year, with a decrease of 67.37% to 74.36% [2] Group 2: Operational Challenges - The decline in performance is attributed to the operating results of its subsidiary, Trademark Plastics Inc. (TPI), which have been negatively impacted by international trade policies and fluctuations in shipping costs [2] - Additionally, the company faces challenges from U.S. tariff policies and domestic medical "group purchasing" policies, leading to a slowdown in demand for some of its products [2]

Core Viewpoint - Gongdong Medical (605369) expects a significant decline in net profit for 2025, projecting a range of 44 million to 56 million yuan, which represents a year-on-year decrease of 67.37% to 74.36% [1] Group 1: Financial Performance - The company anticipates a net profit attributable to the parent company of 44 million to 56 million yuan for 2025 [1] - This projected profit decline is attributed to various factors, including international trade policies and fluctuations in shipping costs affecting the performance of its subsidiary, Trademark Plastics Inc. (TPI) [1] Group 2: Market Conditions - The company is facing challenges due to the impact of U.S. tariff policies and domestic medical "group purchasing" policies, which have led to a slowdown in demand growth for some of its products [1]